<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292161</url>
  </required_header>
  <id_info>
    <org_study_id>ASD-1213-15</org_study_id>
    <nct_id>NCT01292161</nct_id>
  </id_info>
  <brief_title>Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C</brief_title>
  <official_title>Study of Silymarin for Improving Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of silymarin on outcomes of patients
      with hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Silymarin has been claimed to have a beneficial effect in various types of liver injury,
      including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and
      chronic viral hepatitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum aminotransferases (ALT, AST)</measure>
    <time_frame>at six months after admission</time_frame>
    <description>The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV-RNA</measure>
    <time_frame>at six months after admission</time_frame>
    <description>The investigators measured serum HCV-RNA by Polymerase Chain Reaction (PCR) at six months after silymarin admission</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Silymarin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>Tab 210 mg, 630 mg, daily, six months.</description>
    <arm_group_label>Silymarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+)) normal or increased
        liver enzymes (ALT and AST) not using interferon or ribavirin due to patient sensitivity or
        not consenting.

        Exclusion Criteria:

        The pregnant patients patients with side effect which confirmed with rechallenge test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hamid kalantari, A.Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor,Gasteroentrology department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al-zahra university hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://mui.ac.ir</url>
    <description>Isfahan university of medical sciences</description>
  </link>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <last_update_submitted>February 8, 2011</last_update_submitted>
  <last_update_submitted_qc>February 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alireza Yousefy, Associate Professor of Medical Education</name_title>
    <organization>Isfahan University of Medical Sciences</organization>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Silymarin</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

